KAMPALA – As part of CiplaQCIL’s expansion strategy, the company has acquired Quality Chemical Ltd.’s distribution arm of the Cipla India manufactured range of prescription medicines in Uganda.
The acquisition takes the form of a transfer of assets of Quality Chemicals Limited, specifically the sales staff overseeing the human healthcare portfolio, and is expected to boost the company’s sales growth by expanding its product range while unlocking new business opportunities in the retail distribution market.
According to CEO of CiplaQCIL Nevin Bradford, the businesses revenue streams have previously primarily been focused on government and donor-funded sales.
“This recent acquisition is an exciting entry for the business into the private retail pharmaceutical market in Uganda,” he said.
CiplaQCIL will import and distribute the range of medicines manufactured in India by Cipla Limited as well as those manufactured locally in Uganda by CiplaQCIL.
The India range includes medicines for asthma, chronic obstructive pulmonary disease (COPD), diabetes, infections, gastroenterology, and cardiovascular disease.
Distribution of the medicines will commence immediately from CiplaQCIL’s warehouse in Luzira.
“As part of our Africa for Africa strategy and commitment to “caring for life”, we’re proud that CiplaQCIL is able to manufacture and now import and distribute lifesaving medicines to ensure that Ugandans and people from other neighboring countries have easy access to quality, affordable medicines,” said Bradford.
Cipla QCIL revealed that they set out a target to be registered in 22 countries in Africa this year.
During their general meeting on August 20, 2020 the company revealed the scorecard to date is that 16 countries have granted approvals, 15 are in progress, and 3 new country applications will be made this financial year.